Overview

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Patients with eligible diabetic foot ulcers will be screened, treated, and followed for complete ulcer closure. This is a randomized trial. All patients will receive standard-of-care treatment. Additionally, some patients will receive treatment with topical Selinexor gel and some will receive topical placebo gel.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc